Brief: Immuneering Expects Multiple Readouts From Its Phase 1/2A Clinical Trial In 2024
20/02/2024 13:02
Feb 20 (Reuters) - Immuneering Corp IMRX.O :
* IMMUNEERING RECEIVES FDA FAST TRACK DESIGNATION FOR
IMM-1-104 IN
PANCREATIC CANCER
* IMMUNEERING CORP: EXPECTS MULTIPLE READOUTS FROM ITS PHASE
1/2A
CLINICAL TRIAL IN 2024
Source text for Eikon: ID:nGNX8jVLgv
Further company coverage: IMRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Immuneering
See all newsImmuneering expects cash runway to fund operations into 2029
Immuneering posts smaller-than-expected Q1 net loss on lower R&D spend
U.S. STOCKS ON THE MOVE-GoPro, Prudential Financial, Whitestone REIT
U.S. STOCKS ON THE MOVE-US airlines, BlackRock, copper miners
U.S. STOCKS ON THE MOVE-Gap, Caterpillar, Solid Biosciences